| scholarly article | Q13442814 |
| P50 | author | Karen L Kotloff | Q63214788 |
| P2093 | author name string | Levine MM | |
| Sadoff JC | |||
| Formal SB | |||
| Snoy PJ | |||
| Hale TL | |||
| Newland JW | |||
| Herrington DA | |||
| Cogan JP | |||
| Van De Verg L | |||
| P2860 | cites work | Intracellular spread of Shigella flexneri associated with the kcpA locus and a 140-kilodalton protein | Q35090542 |
| Enterotoxin and cytotoxin production by enteroinvasive Escherichia coli | Q35107840 | ||
| Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri | Q36347107 | ||
| Protein synthesis in HeLa or Henle 407 cells infected with Shigella dysenteriae 1, Shigella flexneri 2a, or Salmonella typhimurium W118. | Q36422250 | ||
| Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains | Q36720620 | ||
| Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei | Q36985066 | ||
| Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains | Q36989057 | ||
| Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp | Q37010733 | ||
| Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine | Q37098602 | ||
| Comparison of media for direct isolation and transport of Shigellae from Fecal specimens | Q37156160 | ||
| Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile | Q39252440 | ||
| Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen | Q40168452 | ||
| Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis | Q40211202 | ||
| Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area | Q40776571 | ||
| Studies with a New Generation of Oral Attenuated Shigella Vaccine: Escherichia coli Bearing Surface Antigens of Shigella flexneri | Q40811928 | ||
| Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. | Q40825801 | ||
| Bacterial lipopolysaccharide-induced intestinal microvascular lesions leading to acute diarrhea | Q41018197 | ||
| Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines | Q42966608 | ||
| Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial | Q42982958 | ||
| Inoculum size in shigellosis and implications for expected mode of transmission | Q47172816 | ||
| Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine | Q50201269 | ||
| Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. | Q50464272 | ||
| Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. | Q50464343 | ||
| Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines | Q54022643 | ||
| Immunity in Shigellosis. I. Response of Man to Attenuated Strains of Shigella | Q54040438 | ||
| Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. | Q54362925 | ||
| Immunity in Shigellosis. II. Protection Induced by Oral Live Vaccine or Primary Infection | Q69156182 | ||
| An auxotrophic live oral Shigella flexneri vaccine: development and testing | Q70183127 | ||
| Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati) | Q70422370 | ||
| A correlative study of etiology, clinical features and rectal mucosal pathology in adults with acute infectious diarrhea in southern India | Q93651657 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Shigella flexneri | Q1644417 |
| Escherichia coli K-12 | Q21399437 | ||
| P304 | page(s) | 2218-2224 | |
| P577 | publication date | 1992-06-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen | |
| P478 | volume | 60 |
| Q47205506 | A clinically parameterized mathematical model of Shigella immunity to inform vaccine design. |
| Q40186741 | Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery |
| Q39810262 | Antibody response of monkeys to invasion plasmid antigen D after infection with Shigella spp |
| Q34669980 | Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics |
| Q35210842 | Bacterial Mucosal Vaccines |
| Q93075052 | Clinical endpoints for efficacy studies |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q91801435 | Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints |
| Q34545910 | Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine |
| Q39573053 | Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model |
| Q40939427 | Controlling the cytokine storm in severe bacterial diarrhoea with an oral Toll-like receptor 4 antagonist |
| Q37713347 | Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies |
| Q33617990 | Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo |
| Q35896020 | Enteric pathogens as vaccine vectors for foreign antigen delivery |
| Q36764372 | Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects |
| Q40192692 | Human immune responses against Shigella and enterotoxigenic E. coli: Current advances and the path forward |
| Q35455031 | Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains |
| Q40095911 | Identification of immune correlates of protection in Shigella infection by application of machine learning |
| Q40706785 | Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124. |
| Q40267400 | Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. |
| Q34002438 | Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. |
| Q78171100 | Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines |
| Q91689946 | Regulated Delayed Shigella flexneri 2a O-antigen Synthesis in Live Recombinant Salmonella enterica Serovar Typhimurium Induces Comparable Levels of Protective Immune Responses with Constitutive Antigen Synthesis System |
| Q34008338 | Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults |
| Q35528270 | Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. |
| Q33876179 | Shigella and Shiga toxin-producing Escherichia coli causing bloody diarrhea in Latin America |
| Q34224319 | Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro |
| Q34003433 | Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans |
| Q43432983 | Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. |
| Q34000330 | Strategy for cross-protection among Shigella flexneri serotypes |
| Q34137739 | The Escherichia coli gene pool. |
| Q38035961 | The Shigella human challenge model |
| Q33876803 | Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 |
Search more.